Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Dalriada Drug Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Champignon Brands has selected Toronto-based Dalriada Drug Discovery Inc.to advance its new chemical entity IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 08, 2020
Lead Product(s) : Psilocybine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Dalriada Drug Discovery
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?